RDTCF (Rapid Dose Therapeutics) EPS (Basic): $-0.03 (TTM As of Nov. 2025)


RDTCF Rapid Dose Therapeutics Corp RDTCF
27 GF Score
Price $0.08
GF Value $0.30
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Rapid Dose Therapeutics EPS (Basic)?

Rapid Dose Therapeutics RDTCF -11.11% 27 EPS (Basic) is $-0.03 as of Nov. 2025. GuruFocus rates RDTCF with a GF Score™ of 27/100 and a GF Value™ of $0.30 (Possible Value Trap). The stock has 4 warning signs investors should review.

Rapid Dose Therapeutics's basic earnings per share (Basic EPS) for the three months ended in Nov. 2025 was $-0.01. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Nov. 2025 was $-0.03.

Rapid Dose Therapeutics's EPS (Diluted) for the three months ended in Nov. 2025 was $-0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Nov. 2025 was $-0.03.

Rapid Dose Therapeutics's EPS without NRI for the three months ended in Nov. 2025 was $-0.01. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Nov. 2025 was -0.03.

During the past 3 years, the average EPS without NRI Growth Rate was -0.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was 7.10% per year. During the past 10 years, the average EPS without NRI Growth Rate was 10.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Rapid Dose Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 51.90% per year. The lowest was -53.50% per year. And the median was 22.80% per year.

Rapid Dose Therapeutics  (OTCPK:RDTCF) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Rapid Dose Therapeutics EPS (Basic) Related Terms

Rapid Dose Therapeutics EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Rapid Dose Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rapid Dose Therapeutics EPS (Basic) Chart

Rapid Dose Therapeutics Annual Data
Trend Sep16 Sep17 Sep18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24 Feb25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.02 -0.06 -0.03 -0.03 -0.03

Rapid Dose Therapeutics Quarterly Data
Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 -0.01 -0.01 -0.01
RDTCF
27GF Score
Rapid Dose Therapeutics Corp RDTCF
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rapid Dose Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Rapid Dose Therapeutics's Basic EPS for the fiscal year that ended in Feb. 2025 is calculated as

Basic EPS (A: Feb. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-3.779-0)/124.570
=-0.03

Rapid Dose Therapeutics's Basic EPS for the quarter that ended in Nov. 2025 is calculated as

Basic EPS (Q: Nov. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-0.812-0)/131.675
=-0.01

EPS (Basic) for the trailing twelve months (TTM) ended in Nov. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $-0.03 mean?
Rapid Dose Therapeutics (RDTCF) has a EPS (Basic) of $-0.03 as of Nov. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Rapid Dose Therapeutics and its competitors.
Is Rapid Dose Therapeutics' EPS (Basic) too high?
Rapid Dose Therapeutics' current EPS (Basic) is $-0.03. Overall, Rapid Dose Therapeutics has a GF Score™ of 27/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Rapid Dose Therapeutics' EPS (Basic) compare to VRTX and REGN?
Rapid Dose Therapeutics' EPS (Basic) of $-0.03 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Rapid Dose Therapeutics and its competitors. Rapid Dose Therapeutics's current EPS (Basic) is $-0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapid Dose Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Rapid Dose Therapeutics (RDTCF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.30, compared to a current price of $0.08 — trading 73.3% below its estimated fair value. The current EPS (Basic) is $-0.03. Rapid Dose Therapeutics' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Rapid Dose Therapeutics (RDTCF), the current EPS (Basic) is $-0.03 as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rapid Dose Therapeutics (RDTCF) Overvalued in 2026?

Based on GuruFocus' analysis, Rapid Dose Therapeutics stock appears to be undervalued. The current stock price of $0.08 is trading 73.3% below its estimated GF Value™ of $0.30. GuruFocus considers Rapid Dose Therapeutics to be Possible Value Trap.

Key valuation signals for RDTCF:

  • EPS (Basic): $-0.03
  • GF Value™: $0.30 vs. price of $0.08 (73.3% below fair value)
  • GF Score™: 27/100 with 4 warning signs

No single metric tells the full story. See the RDTCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rapid Dose Therapeutics Business Description

Other Exchanges DOSE:Canada
Address 1121 Walkers Line, Unit 3a, Burlington, ON, CAN, L7N 2G4
Rapid Dose Therapeutics Corp is a Canadian biotechnology company revolutionizing drug delivery through innovation. The company's flagship product QuickStrip is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients (nutraceuticals, pharmaceuticals, vaccines, and cannabis) that are delivered quickly into the bloodstream resulting in rapid onset of the active ingredient.
27GF Score

Get the complete analysis for RDTCF

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.08
Price
$0.30
GF Value